HCV Protease

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1482 Daclatasvir (BMS-790052) <1 mg/mL 148 mg/mL 148 mg/mL
S1538 Telaprevir (VX-950) <1 mg/mL 136 mg/mL <1 mg/mL
S1480 Lomibuvir (VX-222, VCH-222) <1 mg/mL 89 mg/mL 89 mg/mL
S1183 Danoprevir (ITMN-191) <1 mg/mL 144 mg/mL 144 mg/mL
S7579 Ledipasvir (GS5885) <1 mg/mL 100 mg/mL 100 mg/mL
Catalog No. Information Product Use Citations Product Validations

Daclatasvir (BMS-790052)

Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.


Telaprevir (VX-950)

Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM.


Lomibuvir (VX-222, VCH-222)

Lomibuvir (VX-222, VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.


Danoprevir (ITMN-191)

Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2.


Ledipasvir (GS5885)

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.

Tags: HCV protease treatment | HCV protease assay | HCV protease inhibitors review